Table 1.
T cell gene-editing trials in immunotherapy for cancer (as of 9/16/2017)
| Product | Target | Tumor | Start date |
Academia | Industry | Phase | Construct (scFv-CD-SD) |
Gene-editing | Active clinical trials |
Reports | Status | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CCR5KO CD34+ HSC | NA | HIV+hematologic malignancies | May-17 | Affiliated Hospital to Academy of Military Medical Sciences, China | NA | 1 | NA | CCR5 CRISPR KO |
NCT03164135 | NA | R |
| 2 | PD1 KO T cells | NA | Advanced Esophageal Cancer | Mar-17 | Hangzhou Cancer Hospital, China | Anhui Kedgene Biotechnology Co.,Ltd | 2 | NA | PD-1 CRISPR KO | NCT03081715 | NA | R |
| 3 | PD1 KO T cells | NA | Muscle-invasive Bladder Cancer | Sep-16 | Peking University, China | Cell Biotech Co., Ltd. | 1 | NA | PD-1 CRISPR KO | NCT02863913 | NA | NYR |
| 4 | PD1 KO T cells | NA | Castration Resistant Prostate Cancer | Nov-16 | Peking University, China | Cell Biotech Co., Ltd. | 1 | NA | PD-1 CRISPR KO | NCT02867345 | NA | NYR |
| 5 | PD1 KO T cells | NA | Metastatic Renal Cell Carcinoma | Nov-16 | Peking University, China | Cell Biotech Co., Ltd. | 1 | NA | PD-1 CRISPR KO | NCT02867332 | NA | NYR |
| 6 | PD1 KO T cells | NA | Metastatic Nonsmall Cell Lung Cancer | Aug-16 | Sichuan University, China | Chengdu MedGenCell, Co., Ltd. | 1 | NA | PD-1 CRISPR KO | NCT0279385 | NA | R |
| 7 | UCART19 | CD19 | B-cell neoplasms | Nov-16 Aug-16 Jun-16 |
KCL/UCL, London, UK | Servier/Cellectis | 1 | 4g7-CD8-41 BB-CD3z | TCR and CD52TALEN KO |
NCT02735083 NCT02746952 NCT02808442 |
(35) | R R R |
| 8 | UCART19 | CD19 | B-cell leukemia/ lymphoma | Jun-17 | Chinese PLA General Hospital, China | NA | 1 | 4-1 BB-CD3z | TCR, B2M CRISPR KO | NCT03166878 | NA | R |
| 9 | UCART123 | CD123 | BPDCN/AML | Jun-17 Jun-17 |
Weill Cornell Medical College, US | Cellectis S.A | 1 | NA-CD8-41BB-CD3z | TCR and CD52TALEN KO | NCT03203369 NCT03190278 | NA | S S |
| 10 | EBV-CTL | EBV antigens | Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies | Apr-17 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | NA | 1/2 | NA | PD-1 CRISPR KO | NCT03044743 | NA | R |
HIV=human immunodeficiency virus; BPDCN= blastoid plasmocitoid dendritic cell neoplasm; AML=acute myeloid leukemia; R= recruiting; NYR= not yet recruiting